UK orders five million doses of Moderna vaccine, eyes spring arrival
By William James and Alistair Smout LONDON (Reuters) - Britain has secured 5 million doses of an experimental COVID-19 vaccine developed by Moderna Inc after it reported positive trial results, health minister Matt Hancock said on Monday, with the earliest doses expected for delivery in spring. Interim data from a late-stage trial indicated Moderna's vaccine was 94.5% effective in preventing COVID-19
By William James and Alistair Smout
LONDON (Reuters) - Britain has secured 5 million doses of an experimental COVID-19 vaccine developed by Moderna Inc
Interim data from a late-stage trial indicated Moderna's vaccine was 94.5% effective in preventing COVID-19 .
"We have today secured an initial agreement for 5 million doses of the Moderna vaccine," Hancock said at a news conference.
Britain had previously secured supply deals for a total of 350 million vaccine doses from six different suppliers, including Pfizer Inc
Earlier, Prime Minister Boris Johnson's spokesman said the government had prioritised deals with vaccine developers who could provide early supply to Britain and have advanced manufacturing supply chains in place.
Asked if he regretted not being able to buy more of the Moderna vaccine, Hancock said Britain expected to have other vaccines sooner.
"The Moderna vaccine doesn't come on stream until the spring," Hancock said. "I'm just really pleased that we've got those early vaccines that will be available early, and we've already got the orders of those in."
Britain expects to take delivery of the Pfizer vaccine before the Moderna shot becomes available, as well as AstraZeneca's candidate if it proves to be effective.
Deputy Chief Medical Officer Jonathan Van Tam said data from late-stage trials of the AstraZeneca/Oxford vaccine had not been reviewed, so it was still unknown if it works.
But he added that trial results from both the Pfizer and partner BioNTech <22UAy.F> vaccine and Moderna's augured well for other candidates that target the coronavirus ' spike protein.
"This really does begin to show us that the spike protein is a completely plausible and effective target for vaccines to be working against," Van Tam said.
"We're feeling in a happier place than we were. But do we know the (Oxford/AstraZeneca) data? No we don't."
(Reporting by Paul Sandle, Elizabeth Piper, Alistair Smout, Michael Holden and William James, Editing by Kate Holton and Bill Berkrot)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
STOCKHOLM/LONDON (Reuters) - Sweden's decision to ban China's Huawei from its 5G networks restricts free competition and trade, the head of rival telecoms equipment supplier Ericsson told the Financial Times. Swedish telecoms regulator PTS this month halted 5G spectrum auctions after a court suspended parts of its decision that had excluded Huawei from 5G networks over national security risks. "I belong in that category that believes competition makes us longer term a better company
By Devika Krishna Kumar NEW YORK (Reuters) - Oil prices firmed by about 1% on Wednesday on hopes OPEC and its allies will delay a planned increase in oil output and after Pfizer said its COVID-19 vaccine was more effective than previously reported. The market was also supported by a smaller-than-expected increase in U.S. crude stockpiles last week
By Marton Dunai and Alan Charlish BUDAPEST/WARSAW (Reuters) - The prime ministers of Poland and Hungary accused European Union countries of blackmail on Wednesday, digging their heels in after vetoing the bloc's budget and post-COVID recovery package. The two countries on Monday blocked the EU's 2021-2027 budget and the recovery plan, worth a combined 1.85 trillion euros ($2.2 trillion), because access to the funds would be conditional upon respecting the rule of law